1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: DNA Synthesis Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. US DNA Synthesis Market Revenue and Volume, by Service
8.1.1 Oligonucleotide Synthesis
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Gene Synthesis
8.1.2.1. Market Revenue and Volume Forecast
9.1. US DNA Synthesis Market Revenue and Volume, by Application
9.1.1. Research and Development
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Therapeutics
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Diagnostic
9.1.3.1. Market Revenue and Volume Forecast
10.1. US DNA Synthesis Market Revenue and Volume, by End-User
10.1.1. Biopharmaceutical Companies
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Academic and Research Institutes
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Contract Research Organizations
10.1.3.1. Market Revenue and Volume Forecast
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Service
11.1.4.2. Market Revenue and Volume Forecast, by Application
11.1.4.3. Market Revenue and Volume Forecast, by End-User
12.1. LGC Biosearch Technologie
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bioneer Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Thermo Fisher Scientific, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. IBA GmbH
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Twist Bioscience
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Eton Bioscience
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Quintara Biosciences
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Eurofins Scientific
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Integrated DNA Technologies, Inc
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. GenScript Biotech Corporation
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
